Market Overview:
Alirocumab held a dominant share in 2017 owing to its high efficacy and safety profile as compared to other drugs in its class. Clinic settings accounted for a major share of the overall market in 2017 due to rising demand for preventive healthcare services among individuals across all age groups. Geographically speaking, North America held a dominant share of 43% in 2017 followed by Europe which accounted for 27%.
Product Definition:
It is important because high blood cholesterol levels are a major risk factor for heart disease.
AEM-2802:
AEM-2802 is an investigational drug developed by Amgen Inc.
AEM-2814:
LDL cholesterol carries bad cholesterol and can cause heart disease if it stays in the body for long.
Application Insights:
However, incidence rate for both these conditions is expected to increase with aging along with other associated risks such as cardiovascular disease (CVD). This trend is projected to stimulate demand for HCTs thus driving market growth during the forecast period.
On basis of application, the global market has been segmented into clinic based settings including primary care clinics and specialty clinics; hospitals; others which includes home healthcare settings.
Regional Analysis:
North America dominated the global market in 2017. Moreover, increasing R&D investments by major players for development of novel therapies will drive growth in this region.
Asia Pacific is estimated to be fastest-growing regional market over the forecast period due to rising disposable income, improving lifestyle habits such as smoking and alcohol consumption, growing awareness about early diagnosis & treatment options for cardiovascular diseases (CVDs), increase in per capita healthcare expenditure & government initiatives pertaining toward disease management. For instance, In May 2018, Novo Nordisk along with other pharmaceutical companies invested USD X million towards research on diabetes and obesity that affect cardiovascular health programs across Asia Pacific countries including China and India over a period of five years from 2016-2017 financial year. This initiative was taken considering need for new cholesterol lowering drugs among patients suffering from diabetes or obesity.
Growth Factors:
- Increasing prevalence of hypercholesterolemia
- Growing awareness about the benefits of cholesterol-lowering therapies
- Rising demand for novel and more effective hypercholesterolemia treatments
- Technological advancements in the field of hypercholesterolemia treatment 5. Availability of government funding for research and development in the field of hypercholesterolemia treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypercholesterolemia Treatment Market Research Report
By Type
AEM-2802, AEM-2814, Alirocumab, Evinacumab, Others
By Application
Clinic, Hospital, Others
By Companies
CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, LipimetiX Development Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Hypercholesterolemia Treatment Market Report Segments:
The global Hypercholesterolemia Treatment market is segmented on the basis of:
Types
AEM-2802, AEM-2814, Alirocumab, Evinacumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CymaBay Therapeutics Inc
- Daewoong Co Ltd
- Gemphire Therapeutics Inc
- LipimetiX Development Inc
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- The Medicines Company
Highlights of The Hypercholesterolemia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AEM-2802
- AEM-2814
- Alirocumab
- Evinacumab
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypercholesterolemia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypercholesterolemia treatment may include lifestyle changes such as diet and exercise, medications, or a combination of both. Treatment may also involve surgery to remove the blockage in the arteries that causes high cholesterol levels.
Some of the major players in the hypercholesterolemia treatment market are CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, LipimetiX Development Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hypercholesterolemia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hypercholesterolemia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hypercholesterolemia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hypercholesterolemia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hypercholesterolemia Treatment Market Size & Forecast, 2020-2028
4.5.1 Hypercholesterolemia Treatment Market Size and Y-o-Y Growth
4.5.2 Hypercholesterolemia Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AEM-2802
5.2.2 AEM-2814
5.2.3 Alirocumab
5.2.4 Evinacumab
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hypercholesterolemia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hypercholesterolemia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AEM-2802
9.6.2 AEM-2814
9.6.3 Alirocumab
9.6.4 Evinacumab
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AEM-2802
10.6.2 AEM-2814
10.6.3 Alirocumab
10.6.4 Evinacumab
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AEM-2802
11.6.2 AEM-2814
11.6.3 Alirocumab
11.6.4 Evinacumab
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AEM-2802
12.6.2 AEM-2814
12.6.3 Alirocumab
12.6.4 Evinacumab
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AEM-2802
13.6.2 AEM-2814
13.6.3 Alirocumab
13.6.4 Evinacumab
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hypercholesterolemia Treatment Market: Competitive Dashboard
14.2 Global Hypercholesterolemia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CymaBay Therapeutics Inc
14.3.2 Daewoong Co Ltd
14.3.3 Gemphire Therapeutics Inc
14.3.4 LipimetiX Development Inc
14.3.5 Regeneron Pharmaceuticals Inc
14.3.6 RegenxBio Inc
14.3.7 The Medicines Company
